Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer

Jun Kyu Lee, Ji Kon Ryu, Ki Young Yang, Sang Myung Woo, Joo Kyung Park, Won Jae Yoon, Sang Hyub Lee, Kyoung Sin Jeong, Yong Tae Kim, Yong Bum Yoon

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Objectives: Earlier studies that dealt with the combination therapy of gemcitabine and histone deacetylation inhibitors for pancreatic cancer revealed unsatisfactory results. The activation of nuclear factor κB (NF-κB) was referred as one of the attributable causes, and we attempted to overcome this resistance by the addition of a proteasome inhibitor. Methods: The influences of suberoylanilide hydroxamic acid (vorinostat, SAHA), a histone deacetylase inhibitor, and bortezomib, a novel selective antagonist of 26S proteasome, with or without gemcitabine on cell growth and apoptosis and the expressions of related proteins were observed in pancreatic cancer cell lines (MiaPaCa-2 and ASPC-1). The xenograft model of pancreatic cancer was used to notice effects in vivo. Results: Vorinostat and bortezomib had independent inhibitory effects and potentiated the antitumor property of gemcitabine in vitro. In the xenograft model, more augmented effects were achieved when bortezomib was combined with gemcitabine than gemcitabine alone. The down-regulation of pAkt and suppression of NF-κB activity was induced by the triple combination. Conclusions: The triple combination of vorinostat, bortezomib, and gemcitabine resulted in the strongest antitumor effects both in vitro and in vivo and pAkt and NF-κB seems to be involved in this process.

Original languageEnglish
Pages (from-to)966-973
Number of pages8
JournalPancreas
Volume40
Issue number6
DOIs
StatePublished - Aug 2011

Keywords

  • Akt
  • NF-JB
  • bortezomib
  • gemcitabine
  • pancreatic cancer
  • vorinostat

Fingerprint

Dive into the research topics of 'Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer'. Together they form a unique fingerprint.

Cite this